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Abstract
5-Lipoxygenase metabolizes arachidonic acid (AA) to generate leukotrienes
(LTs). Leukotrienes are very potent inflammatory mediators that can have negative
effects on bone healing and cartilage tissue generation. Recent studies have shown that
decreasing 5-lipoxygenase (5-LO) activity during fracture healing accelerates
endochondral ossification and decreases healing time in animal fracture models, however,
the roles of 5-LO in chondrogenesis is not fully investigated. In this study, we tested the
hypothesis that 5-LO inhibition will increase the process of chondrogenesis. The ABT761 is an N-hydroxyurea analog structurally similar to zileuton, which is a 5-LO enzyme
inhibitor. The ATDC5 cell line which is derived from teratocarcinoma cells of mice is a
chondrogenic cell line. The ATDC5 cells were treated with ABT-761 and Insulin. Then,
they were evaluated for cellular proliferation via colorimetric assay, 5-LO gene
expression via Immunocytochemistry (ICC) and Immunoblotting (Western Blot), and
chondrogenesis by measuring calcium deposition, proteoglycan synthesis via Alizarin
Red stain and Alcian Blue stain respectively at specific time points 7 days, 14 days, 21
days and 28 days. Our data demonstrated that ATDC5 cells express a 5-LO protein which
can be directly inhibited by ABT-761 treatment. At a concentration of 10 µM, ABT-761
treatment does not affect ATDC5 cellular proliferation, however, higher doses inhibit
significantly. In term of chondrogenesis, in this study, we demonstrated that 1µM ABT761 has no effect on chondrogenesis, neither increase nor decrease, in ATDC5
chondrogenic cell line. In contrast, concentrations of 10 µM and 100µM ABT-761 have
negative effects on chondrogenesis through which ABT-761 promotes chondrocyte
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apoptosis that may potentially lead to accelerating endochondral ossification or long bone
formation in patients with a long bone fracture. However, ABT-761 may not be a clinical
value to regenerate or promote chondrogenesis in patients suffering from osteoarthritis.

Key words: osteoarthritis, chondrocyte, chondrogenesis, ossification, ABT-761,
ATDC5 cell.

4

Introduction
Cartilage biology
Cartilage is a strong, flexible and semi-rigid supporting connective tissue. Like all
connective tissue, cartilage consists of cells called chondrocytes and extracellular matrix
(ECM). Chondrocytes are highly specialized cells which are derived from mesenchymal
stem cells and occupy from 1% to 5% of total cartilage tissue (Bhosale and Richardson
2008). They are metabolically active cells that proliferate and secrete ECM to maintain,
sustain, and repair the cartilage (Akkiraju and Nohe 2015). Cartilaginous extracellular
matrix is composed of 70-80% water, 10-25% collagen fibers which have high amounts
of type II collagen, and 5-15% proteoglycans (PGs) which have a large composition of
aggrecans (Horkay 2012) that contain non-collagenous protein and glycoproteins
including glycosaminoglycan (GAG) and hyaluronic acid (HA) (Gao, Liu et al. 2014).
Water and proteoglycans provide cartilage tissues compressive strength while the
collagenous network is responsible for the tensile strength (Bautista, Park et al. 2016).
The three-dimensional network of ECM is formed by the triple-helical collagen fibrils.
The major cartilage PG is the bottle brush aggrecan molecule, which interacts with
hyaluronic acid (HA) to form large proteoglycan aggregates (size 1-4 micrometers) or
aggrecan-HA complexes. These complexes are embedded in the fibrous collagenous
network (Horkay 2012) (Figure 1).
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Figure 1 shows the hierarchy of cartilage extracellular matrix
organization. (A) Aggrecan bottlebrush. (B) Aggrecan-HA complex.
(C) Aggrecan-HA complexes aggregates in the collagenous network
(Horkay 2012)

There are three types of cartilages, including hyaline cartilage, elastic cartilage,
and fibrous cartilage. Elastic cartilage is found at the external ear, ear canal, epiglottis of
the larynx. Fibrous cartilage is found in intervertebral disks of the vertebral column and
menisci of the knee, forms the attachment of ligaments and tendons to bone. Hyaline
cartilage comprises cartilage at synovial joint including shoulders, elbow, hips, sternum,
and cartilage of nasal septum, larynx, trachea, and bronchi. Hyaline cartilage is also
called articular cartilage and is 2-4 mm thick (Sophia Fox, Bedi et al. 2009). There are
two important functions that articular cartilage performs. First, along with synovial fluid,
articular cartilage provides virtually friction-free movement within the joint. Second,
cartilage spreads the load in weight-bearing joints across the joint surface, which allows
the underlying bones to absorb the shock and weight. Hence, articular cartilage functions
require it to be elastic and to have high tensile strength. These characteristics are
provided by ECM components, proteoglycans and Type II collagen, which are both
produced by chondrocytes (Bautista, Park et al. 2016). Similar to bone tissue, cartilage
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degrades and replaces its matrix constantly. Unlike bone tissue, however, cartilage is
devoid of blood vessels, lymphatics and nerves, therefore, cartilage has very limited
capability to heal and repair in a harsh biochemical condition (Sophia Fox, Bedi et al.
2009). Nutrition is supplied through simple diffusion of synovial fluid. Thus, the
regeneration capacity of articular cartilage is very limited. As a result, injuries that do not
penetrate the subchondral bone cannot self-repair in adults (Dehne, Karlsson et al. 2009).

Chondrogenesis and chondrocyte differentiation during development
Cartilage has an important function by serving as a template for long bone
formation through endochondral ossification (Kronenberg 2003). Chondrogenesis is a
complex process that leads to establishments of cartilage. During embryogenesis,
cartilage is the first skeletal tissue to be formed that leads to the formation of all mature
cartilage and long bones, except flat bones (Quintana, zur Nieden et al. 2009). Flat bone
is formed through intramembranous ossification, while long bone formation is through
endochondral ossification. The process of cartilage formation starts when mesenchymal
stem cells (MSCs) condense to form a dense cell mass. Then MSCs proliferate and
differentiate into chondroblasts. Some of these cells give rise to mature chondrocytes. If
mature chondrocytes undergo endochondral ossification, or long bone formation,
cartilage is vascularized, ECM becomes degraded, hypertrophic chondrocyte become
apoptotic, and osteoblasts invade the free space within the tissue (Hoffman, Weston et al.
2003), (Mackie, Ahmed et al. 2008). (Figure 2). As chondrogenesis plays important roles
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in the formation of both mature cartilages and bones, any errors occurring during this
crucial process can affect cartilage formation and long bone formation.

Figure 2 shows the schematic of chondrogenesis and endochondral ossification

Chondrogenesis can be divided into five main stages, each stage is the occurrence
of a specific event. (A) Condensation and proliferation of MSCs, (B)
Differentiation of MSCs into chondroblasts, (C) Chondroblast become
chondrocytes (D) Mature chondrocytes become hypertrophy, (E) if cartilage
tissue undergoes endochondral ossification hypertrophic chondrocytes become
apoptotic, cartilage is vascularized, and osteoblasts invade the tissue

(Quintana, zur Nieden et al. 2009)
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Arachidonic acid and leukotriene biosynthesis
Arachidonic acid (AA) is the precursor of prostaglandins and leukotrienes, which
are lipid signaling molecules. In mammals, Cyclooxygenase 1 and cyclooxygenase 2
(COX 1 and COX 2) are the key enzymes in prostaglandins biosynthesis, while 5lipoxygenases (5-LO), is a key enzyme in leukotriene biosynthesis. Despite having
approximately 60% identical primary structures and performing almost the same catalytic
function (Simmons, Botting et al. 2004), COX 1 is constitutively expressed in most
tissues, while COX 2 is induced (Tanabe and Tohnai 2002). COX2 metabolizes AA to
generate cyclo-endoperoxides including prostaglandin H2 (PGH2), which is subsequently
converted into PGD2, PGE2, PGF2, PGI2, and thromboxane A2 (TXA2). In leukotriene
biosynthesis, 5-LO converts AA into 5 hydroxy-peroxy-eicosatetraenoic acid (5HPETE),
which is then converted into intermediate leukotriene A4 (LTA4), then into leukotriene
B4 (LTB4) by enzyme leukotriene A4 hydrolase (LTA4H), leukotriene C4 (LTC40,
leukotriene D4 (LTD4), leukotriene E4 (LTE4) by enzyme LTC4 synthase (LTC4S)
(O'Connor, Manigrasso et al. 2014). (Figure 3).
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Figure 3: Prostaglandin and Leukotriene biosynthesis (O'Connor, Manigrasso
et al. 2014) shows schematic of pathway for synthesis and signaling of

arachidonic acid, docosahexaenoic acid, and eicosapentaenoic acidderived lipid mediators. The diagram summarizes some of the synthetic
pathways for lipid mediator synthesis. Lipid mediators and synthetic
intermediates and active products are shown in black text. Enzyme
activities are shown in red text. Receptors are shown in green text. Known
effects of receptor activation on intracellular cyclic adenosis
monophosphate or calcium levels are shown at the bottom.
.
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Prostaglandins and leukotrienes biosynthesis have been showed to be important in
the process of chondrogenesis and endochondral ossification or long bone formation.
Leukotrienes are very potent inflammatory mediators that can have negative effects on
long bone healing and cartilage tissue generation. Recent studies have shown that
decreasing 5-LO activity during long bone fracture can accelerate endochondral
ossification, decrease healing time, and increase osteogenesis in animal models Other
studies also proved that leukotriene antagonism, using montelukast sodium which is
leukotriene type 1 receptor antagonist and zileuton which is a 5-LO enzyme inhibitor, can
enhance fracture repair on mice modal by increasing chondrocyte proliferation and early
endochondral bone formation (Wixted, Fanning et al. 2009). Licofelone (ML-3000), a
dual inhibitor of 5-LO and COX, has been shown to reduce the level of cartilage
chondrocyte death in vivo in experimental dog osteoarthritis (Boileau, Martel-Pelletier et
al. 2002). these experimental findings indicate that pharmacological manipulation of the
arachidonic acid pathway could be a means to accelerate or enhance chondrogenesis. In
fact, there are a great number of compounds targeting 5-LO or its cofactor, 5Lipoxygenase-Activating factor (FLAP), which have been used to treat chronic
obstructive pulmonary diseases ((Poff and Balazy 2004), (Carter, Young et al. 1991,
Evans, Ferguson et al. 2008),(Muller-Peddinghaus, Fruchtmann et al. 1993). In addition,
compounds targeting leukotriene receptors or prostaglandin receptors have been used to
treat ophthalmic conditions, asthma, and other medical conditions (Jones, Labelle et al.
1995), (Alexander, Miller et al. 2002).
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Relation to public health and purpose of the thesis
As chondrogenesis is the important process in the formation of mature cartilage
and endochondral ossification (Quintana, zur Nieden et al. 2009), pharmacological
methods to promote chondrogenesis would be of clinical value for osteoarthritis and long
bone fractures. Osteoarthritis (OA) is a clinical syndrome that is characterized by
cartilage degradation that leads to joint failure, in addition to stiffening of joints, and
functional limitation (Akkiraju and Nohe 2015). With OA, the cartilage within the joint
pathologically lost hyaline or articular cartilage itself, subchondral sclerosis development,
osteophyte formation, and meniscus and bone marrow degradation (Joseph, Baum et al.
2012), ligamentous laxity, and subchondral bone changes (Bennell, Hunter et al. 2012).
Joints affected by OA are peripheral joints which include large joints such as the knees,
hips, and small joints such as hand joints. As these joints are important to carry out daily
activities, the pain from these joints can reduce joint functions and effect on patients’
quality of life. Not only does OA impact the individual, OA can also have large impact
on society, affecting almost 27 million Americans or 12.1% of the adult population. It is
estimated that the United States spends $185 billion in management of OA annually
(Neogi 2013). Thus, methods that could regenerate or promote chondrogenesis would be
of substantial benefit to patients and would reduce the societal burden caused by OA.
Usually, patients suffering from OA receive both pharmacological ( such as celecoxib,
rofecoxib, which are nonsteroidal anti-inflammatory drugs or NSAIDS, acetaminophen,
capsaicin cream) and non-pharmacological treatments (such as exercise, aerobic or
strengthening or water-based, arthroplasty). Although, these treatment options can relieve
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symptoms or improve functionality temporarily, pharmacological options are known to
have adverse side effects such as gastrointestinal (GI) toxicity of NSAIDs and increased
risk of myocardial associated with rofecoxib (Zhang, Moskowitz et al. 2007).
In this study, we hypothesize that direct pharmacological inhibition of 5-LO would
accelerate and enhance chondrogenesis and may contribute to the improved bone healing
effects observed in the rodent fracture models where 5-LO expression was inhibited
(Cottrell, Keshav et al. 2013). Our hypothesis was tested with the use of ATDC5
chondroprogenitor cells treated with a direct 5-LO inhibitor, ABT-761. The ATDC5 cell
line is derived from the mouse teratocarcinoma cells and has been characterized as a
chondrogenic cell line which goes through a sequential process analogous to chondrocyte
differentiation. ATDC5 cell line was chosen over a mice model because these cells are
easy to handle and their differentiation into chondrocytes is easily detectable and have
been used to assess for chondrogenesis as previous studies (Choi, Nepal et al. 2011),
(Altaf, Hering et al. 2006). ABT-761 is a N-hydroxyurea analog which functions as a
direct 5-LO enzyme inhibitor. ABT-761 exhibits potent and selective inhibition of
leukotriene formation. As calcium and proteoglycan deposition occur during
chondrogenesis, quantification of these matrix components is used to assess
chondrogenesis.
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Methodology
Cell culture
The ATDC5 cell line was utilized and stored at -80 C when not in use. Cells were
cultured under 5% CO2 in growth media, which consisted of Dulbecco’s Modified
Eagle’s Medium (DMEM)/Hams F-12 50/50 (Corning ®, Manassas, Virginia, USA) Mix
supplemented with 5% fetal bovine serum (FBS), 1% L-Glutamine, 1%
Penicillin/Streptomycin, 1% Selenium, and 1% Transferrin at 37°C. Cells were checked
periodically (every 2-3 days) using a Leica DMi1 FOV20 inverted microscope (Leica,
Chicago, IL, USA) to determine confluence, the possibility of contamination, and cell
death. When the cells reached 100% of confluence, the experimental treatments were
conducted as described below.

ABT-761 treatment
ATDC5 cells were treated with increasing doses of 5-LO inhibitor, ABT-761
(Abbott, Abbott Park, IL, USA), (1 µM, 10 µM, 100 µM, 1000 µM) in triplicate over
specific time points (24 and 48 hours, and 1, 2, 3, 4 weeks) and/or with Insulin
(Invitrogen, Waltham, MS, USA) (INS) at increasing doses (0.1% and 1%).
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Cellular proliferation
ATDC5 cells were seeded in a 96-well plate at a density of 8000 cells per well
and allowed to adhere for 24 hours at 37°C in a CO2 incubator. After 24 hours of
incubation, culture media were replaced with the 12 different treatment groups (media,
media and 0.1% INS, media and 1% INS, media and 10 µM ABT, media and 10 µM and
0.1% INS, media and 10 µM ABT and 1% INS, media and 100 µM ABT, media and
0.1% INS and 100 µM ABT, media and 1% INS and 100 µM ABT, media and 1000 µM
ABT, media and 0.1% INS and 1000 µM ABT, media and 1% INS and 1000 µM ABT).
Then the cells were incubated for 24 hours at 37°C in a CO2 incubator. Subsequently, 10
µL of yellow MTT solution (5 mg/ml in Phosphate-Buffered Saline (PBS), 1X, without
Calcium and Magnesium, Corning®, Manassas, Virginia, USA) was added to each well
and the 96-well plate was incubated for 4 hours at 37°C in a CO2 incubator. Then the
mixture of treatment and MTT solution was aspirated from each well. Next, the formed
formazan crystals were solubilized by adding 100 µL of Dimethyl Sulfoxide (DMSO),
(Sigma-Aldrich ®, USA), per well. Each plate was covered with aluminum foil and
incubated at room temperature for 2 hours while shaking. Finally, the intensity of the
dissolved intracellular purple formazan crystal was quantified by measuring the
absorbance at a wavelength of 570 nm using spectrophotometry SpectraMax M5. In order
to quantify % of cellular proliferation, the absorbance value reading of the blank must be
subtracted from all samples. Absorbance reading from test samples must then be divided
by those of the control and multiplied by 100 to give percentage cell viability or
proliferation. The formula was shown in Figure 4. If the absorbance values are greater
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than the control, this indicates increased cell proliferation, but if the absorbance values
are lower than the control this suggests cell death or inhibition of cellular proliferation.

Figure 4: formula for determine cellular proliferation

Immunocytochemistry
ATDC cells were seeded in quadruplet in an 8-chamber polystyrene vessel tissue
culture treated glass slide (Falcon Corning ®, Big Flats, New York, USA ) at a density of
80,000 cells/300µL per well and allowed to adhere for 24 hours at 37°C in a CO2
incubator. After 24 hours of incubation, the culture medium was replaced with 4 different
treatment groups (media, media and 10 µM ABT, media and 1% INS, media and 1% INS
and 10 µM ABT). At timepoints of 24 and 48 hours, the immunocytochemistry was
conducted. First, the media in the chambers was aspirated, then the chamber was washed
one time with PBS. Next, the cells were fixed in 5 minutes with -20°C methanol. Then,
the fixative -20°C methanol was aspirated, and the chamber was rinsed 3 times with icecold PBS. After that, the chambers were incubated with 300 µL blocking reagent,
SuperBlock™ Blocking Buffer in PBS (Thermo Scientific, Rockford, Illinois, USA ) to
block unspecific binding for 1 hour at room temperature. Subsequently, the blocking
reagent was aspirated, and the chambers were incubated with primary antibodies, 5-
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Lipoxygenase (5-LO) mouse monoclonal antibody, (Santa Cruz Biotechnology, Inc.,
Dallas, Texas, USA) (sc-136195), at 1:25 dilution at 4°C overnight. On the following
day, the chamber was washed 3 times with PBS), 1X, without Calcium and Magnesium,
(Corning®, Manassas, Virginia, USA), for 5 minutes and gentle shaking. Then the
chamber was incubated with secondary antibodies, mouse-IgG kappa BP-HRP which is a
purified recombinant mouse IgG kappa light chain binding protein conjugated to
horseradish peroxidase (HRP), (Santa Cruz Biotechnology, Inc., Dallas, Texas, USA)
(sc-516102), at 1:25 dilution for 2 hours. After that, the chambers were washed 3 times
with PBS for 5 minutes while gently shaking. Next, the chambers were incubated with
Hydrogen peroxide 30% solution and DAB Substrate System, (VWR Company, Solon,
Ohio, USA) for 2 to 5 minutes following the manufacturer’s instructions. Then the
chambers were washed 2 times with diH2O. After that, the safe removal fixture kit was
used to remove the chamber out of the slide. Finally, the slides were dehydrated through
alcohol and xylenes as follows: soak in 90% ethanol twice for 3 minutes each, then 100
% twice for 3 minutes each. Immediately, 1-2 drops of permanent Acrytol Mounting
Media, (Leica Biosystems, Buffalo Grove, IL, USA) were added on the slides and
covered with glass coverslips. Each slide was observed by Olympus BX53 Microscope
at 200X magnification, and Osteomeasure software was used to quantify the DAB
staining procedure and document the images.
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Protein Isolation
First, adherent ATDC5 cells treated with six treatment groups (0.1% INS, 1%
INS, 0.1%INS and 10 µM ABT, 1% INS and 10 µM ABT, 10 µM ABT, and media only)
were harvested with Mammalian Protein Extraction Buffer (Thermo Fischer Scientific,
Handouver Park, IL, USA) while on ice. Six different treatment groups were aspirated
from the plates, rinsed with cold 1x HBSS, then 1X HBSS was aspirated. Mammalian
Protein Extraction Buffer was added to each well and the plate was placed onto a shaker
for ten minutes to coat cells evenly while on ice. Next, a cell scraper was used to remove
adherent cells off the plate, assist in cell lysis, and protein extraction. The protein lysates
collected from each well were stored in the -20°C freezer until needed for further
analysis.

Western Blotting
Triplicate sets of frozen protein samples in Mammalian Protein Extraction Buffer
were thawed on ice until completely defrosted to prevent protein degradation. In separate
microtubes, protein sample and 2X SDS with 2-Mercaptoethanol (2-Me) were combined
in a 1:1 ratio and centrifuged at 4 C. Protein mixture was heated in a dry bath at 70°C for
10 minutes to denature the protein. A 4-12% NuPAGE Bis-Tri gel (Thermo Fischer
Scientific, Handover Park, IL, USA) was run using NuPAGE MOPS Running Buffer
solution (Thermo Fischer Scientific, Handover Park, IL, USA) and run for 50 minutes at
200V. In preparation for gel transfer, the transfer apparatus and four pieces of filter paper
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were soaked in a transfer buffer solution with 10-20% methanol; polyvinylidene fluoride
(PVDF) membrane was also soaked for one minute in methanol only and rinsed in the
NuPAGE transfer buffer solution. After the running gel was complete, proteins affixed to
the gel were transferred to the polyvinylidene difluoride (PVDF) membrane following the
manufacturer’s directions. Following transfer, PVDF membrane was placed in
SuperBlock solution (ThermoScience, Rockford, IL) and rocked at room temperature for
1 hour.
After 1 hour, the PVDF membrane was rinsed 3 times in 1x Transfer Buffer
Saline with 0.1% TWEEN (TBS-T) for 5 minutes, then placed in primary antibody
solution, and slowly shaken overnight in 4°C refrigerator. The primary antibody solution
consisted of 5-Lipoxygenase (5-LO) mouse monoclonal antibody, Santa Cruz
Biotechnology, Inc., Dallas, Texas, USA (sc-136195, and 0.1% SuperBlock™ Blocking
Buffer in PBS (Thermo Scientific , Rockford, Illinois, USA ). Internal control for 5-LO
protein expression is beta-actin gene. After overnight incubation, the PVDF membrane
was rinsed 3 times in 1X TBS-T for 5 minutes of each rinse, then placed in secondary
antibody solution, and rocked at room temperature for 1 hour. The second antibody
solution consisted of anti-mouse IgG-conjugated antibody, TBS-T and 0.1% SuperBlock.
The membranes were rinsed twice in 1X TBS-T and once in 1X TBS to remove any
remaining secondary antibodies, then placed in Pierce ® Enhanced Chemiluminescence
(ECL) Western Blotting substrate (Thermo Fischer, Handover Park, IL, USA) to view
under UltraViolet light using FluorChem E system (ProteinSimple, San Jose, CA, USA).
Then the image result was analyzed by using Alpha View software in which the analysis
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tool and multiplex band analysis tool were used, the 5-LO protein expression
was normalized using beta-actin gene.

Alcian Blue Staining
In order to detect proteoglycan deposition, Alcian Blue Assay was used. First, the
ATDC5 cells were plated in triplicate in 24 well-plate at a density of 50,000 cells/500 µL
per well. After 2 days of incubation for confluence at 37⁰C in a CO2 incubator, the
growth media was replaced with 8 different treatment groups including media, media
and 1 µM ABT, media and 10 µM ABT, media and 100 µM ABT, media and 1% INS,
media and 1% INS and 1 µM ABT, media and 1% INS and 10 µM ABT, media and 1%
INS and 100 µM ABT, and the time points of 1, 2, 3, 4 weeks, the cells were harvested.
At each time point, on the day 1 of the Assay, the 24-well plates were rinsed twice with
PBS then fixed with 100% cold methanol for 5 minutes. Next, the plates were stained
with 0.1% Alcian Blue in 0.1 M HCl overnight at room temperature. The following day,
the 24-well plates were rinsed 3 times with HBSS. Then, proteoglycan was extracted with
6 M Guanidine-HCl overnight. Lastly, the proteoglycan concentration was quantified by
measuring the absorbance at a wavelength of 595 nm using a spectrophotometer.
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Alizarin Red Staining
In order to detect calcium deposition, Alizarin Red Assay was used. Like Alcian
Blue Stain protocol, the ATDC5 cells were plated in triplicate in 24 well-plate at a
density of 50,000 cells/ 500 µL per well. After 2 days of incubation for confluence at
37°C in a CO2 incubator, the growth media was replaced with 8 different treatment
groups including media, media and 1 µM ABT, media and 10 µM ABT, media and 100
µM ABT, media and 1% INS, media and 1% INS and 1 µM ABT, media and 1% INS
and 10 µM ABT, media and 1% INS and 100 µM ABT. At timepoints of 1, 2, 3, 4 weeks,
the cells were harvested. The 24-well plates were rinsed 2 times with PBS then fixed with
10% (v/v) formaldehyde at room temperature for 15 minutes. Next, the plates were rinsed
2 times with diH2O, and 1 mL of 40 mM Alizarin Red dye solution was pipetted into
each well. Then, the 24-well plates were incubated for 20 minutes at room temperature.
After that, the Alizarin Red dye was aspirated, the plates were washed 4 times with
diH2O while shaking for 5 minutes of each wash. To facilitate the removal of any
remaining liquid, the plates were left at an angle for 2 minutes and re-aspirated. After
that, the plates were stored in -20⁰C freezer. On the following day, 800 µL of 10% (v/v)
of Acetic acid was added to each well, then the plates were incubated at room
temperature for 30 minutes while shaking. Using a cell scraper, the monolayer was
scraped from the plate and transferred with 10% (v/v) acetic acid to clean centrifuge
tubes. The centrifuge tubes were then vortexed briefly for 30 seconds, then warmed for
10 minutes at 85°C. Afterward, the centrifuge tubes were placed on ice for 5 minutes then
centrifuged at 13,000 rpm for 15 minutes. Next, 500 µL of supernatant was transferred to
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new centrifuge tubes. Then, 200 µL of 10% (v/v) ammonium hydroxide was added to the
supernatant. Finally, 150 µL of supernatant was pipetted in triplicate into a 96-well plate,
then the calcium deposition was quantified by measuring the absorbance at a wavelength
of 405 nm using a spectrophotometer.
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Results
The results of the MTT assay shows that 10µM ABT does not affect cellular
proliferation compared to the control. However, at higher concentrations, ABT
significantly inhibits cellular proliferation (Figure 5).
The MTT assay result shows that 10 µM ABT (Rx3) does not affect cellular
proliferation (113%, p > 0.05) compared to the controls, including media only (Rx1),
0.1% INS (Rx2), 1% INS (Rx9). However, at higher concentrations of 1000 µM,
including Rx3 vs Rx7 (10 µM ABT vs 1000 µM ABT), Rx3 vs Rx8 (10 µM ABT vs
0.1%INS & 1000 µM), Rx 3 vs Rx12 (10 µM ABT vs 1%INS & 1000 µM), ABT
significantly inhibits cellular proliferation, which decreases 51.5%, 52,8%, 52%
respectively, p-value < 0.05. At concentrations of 100 µM, on the other hand, ABT does
not inhibit cellular proliferation, Rx3 vs Rx5 (10 µM ABT vs 100 µM ABT), p> 0.05.
Therefore, the concentration of ABT was capped in at 100 µM and one more
concentration of ABT, which was 1 µM, was added for the following experiments to
elucidate the effects of ABT on chondrogenesis. It is also noticed that there is no
difference in the concentration of insulin at 0.1% and 1.0% regarding cellular
proliferation in the controls group (Rx2 vs Rx9), as well as in the presence of 10 µM
ABT (Rx4 vs Rx10) (Figure 5), (Table1, 2).
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Figure 5: Cellular proliferation of ATDC-5 cells post ABT-treatment. ATDC-5 cells
treated with 10 µM, 100 µM, 1000 µM ABT in combination with 0.1% and 1% insulin
for 24 hours (Rx3,4,10,5,6,11,7,8,12_treatment groups).
Control groups included cells treated in media only, and media in combination with 0.1
% and 1% insulin (Rx1,2,9).
(A) The absorbance value of ATDC5 cell in each treatment group at 24 hours-post
treatment.
(B) Cellular proliferation values calculated for ATDC5 cells in each treatment group at
24 hours-post treatment.
(C) Image of wells for each ATDC5 cell treatment group after completion of MTT assay.
Error bars represented Mean +/- SD. Photographed by the author, Tien My Tran, at
Seton Hall University, South Orange, New Jersey, USA, in May 2019.
(*) denoted statistically significant differences between treatment groups where
appropriate; corresponding p-value were noted.
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One Way Analysis of Variance
Group Name

Mean
SEM
(0.1%INS)

RX 2

Std Dev

116.983

10.808

82.516

30.559

113.068

33.693

103.685

14.563

75.554

8.232

65.866

8.160

64.916

12.587

50.257

14.903

61.615

4.660

60.303

5.171

61.475

11.846

6.240
RX 9
RX 3
RX 4
RX 10
RX 5
RX 6
RX 11
RX 7
RX 8
RX 12

(1.0%INS)
17.643
(10 uM ABT)
19.453
(0.1%INS &10 uM ABT)
8.408
(1.0%INS & 10 uM ABT )
4.753
(100 uM ABT)
4.711
(0.1%INS & 100 uM ABT)
7.267
(1%INS & 100 uM ABT)
8.604
(1000 uM ABT)
2.691
(0.1%INS & 1000 uM ABT)
2.985
(1%INS & 1000 uM ABT)
6.840

Table 1: cellular proliferation percentage in each treatment group compare to control
(Rx1) which is 100%
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Comparison

Diff of Means (%)
P
P<0.050
RX 2 vs. RX 11 (0.1%INS vs 1%INS & 100 uM ABT)
66.725
0.002
Yes
RX 3 vs. RX 11 (10 uM ABT vs 1%INS & 100 uM ABT)
62.811
0.005
Yes
RX 2 vs. RX 8 (0.1%INS vs 0.1%INS & 1000 uM ABT)
56.680
0.015
Yes
RX 2 vs. RX 12 (0.1%INS vs 1%INS & 1000 uM ABT)
55.507
0.018
Yes
RX 2 vs. RX 7 (0.1%INS vs 1000 uM ABT)
55.368
0.019
Yes
RX 4 vs. RX 11 (10 uM ABT & 0.1%INS vs 1%INS & 100 uM ABT) 53.427
0.027
Yes
RX 3 vs. RX 8 (10 uM ABT vs 0.1%INS & 1000 uM ABT )
52.766
0.030
Yes
RX 2 vs. RX 6 (0.1%INS vs 0.1%INS & 100 uM ABT)
52.067
0.033
Yes
RX 3 vs. RX 12 (10 uM ABT vs 1%INS & 1000 uM ABT )
51.593
0.036
Yes
RX 3 vs. RX 7 (10 uM ABT vs 1000 uM ABT )
51.454
0.036
Yes
RX 2 vs. RX 5 (0.1%INS vs 100 uM ABT )
51.117
0.038
Yes
RX 1 vs. RX 11 (media only vs 1%INS & 100 uM ABT)
49.743
0.048
Yes
RX 3 vs. RX 1 (10 uM ABT vs media only )
13.068
1.000
No
RX 2 vs. RX 3 (0.1%INS vs 10 uM ABT)
3.914
1.000
No
RX 3 vs. RX 9 (10 uM ABT
vs 1.0% INS)
30.552
0.669
No
RX 3 vs. RX 5 (10 uM ABT vs 100 uM ABT)
47.203
0.074
No
RX 2 vs. RX 9 (0.1%INS vs 1.0% INS)
34.466
0.458
No
RX 4 vs. RX 10 (10 uM ABT & 0.1%INS vs 10 uM ABT & 1%INS)
28.131
0.799
No

t
5.083
4.785
4.318
4.229
4.218
4.070
4.020
3.966
3.930
3.920
3.894
3.789
0.996
0.298
2.327
3.596
2.626
2.143

Table 2: statistical analysis for the cellular proliferation in each treatment group of the
MTT assay in Figure 1.
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The Immunocytochemistry shows ATDC5 cells do express 5-Lipoxygenase (5LO) protein in growth and differentiation phase, and the 5-LO protein can be inhibited in
the presence of the inhibitor, ABT-761 (Figure 6,7). The results of
Immunocytochemistry show that at both 24 and 48-hour post-treatment, there is an
increase in 5-LO protein expression in both only media group (Rx1) and 1%INS group
(Rx9). However, the 5-LO protein expression decreases in the presence of 10 µM ABT
(Rx3_only 10 µM ABT, and Rx 10_1%INS+10 µM ABT).

28

Figure 6: Immunocytochemistry of ABT-treated ATDC5 cells. ATDC5 cells were plated
at 50% and allowed to reach confluency, then the media was replaced with 4 treatment
groups: Rx1 (just Media), Rx3 (10µM ABT), Rx9 (1%INS), Rx10 (10µM ABT + 1%
INS). Subsequently, the Immunocytochemistry was conducted at two time points: 24
hours-post treatments (A, B, C, D), and 48 hours-post treatments (E, F, G, H). ATDC5
cells stained for 5-LO protein using the primary antibody, 5-Lipoxygenase (5-LO) mouse
monoclonal antibody, (Santa Cruz Biotechnology, Inc., Dallas, Texas, USA) (sc-136195)
and then DAB substrate. Finally, 5-LO protein expression can be visualized as brown
spots, which are denoted by orange arrows. Photographed by the author, Tien My Tran,
at Rutgers University, Newark, New Jersey, USA, in May 2019.

24 hours post Rx

48 hours post Rx

Rx1 _ Media Rx3_1uM ABT
Rx9_1% INS
Rx10_1uM ABT + 1%INS
74
45
96
85
37
93
89
52
104
93
48
107
96
37
100
99
48
97

Table 3: Brown spot counting data using an Olympus BX53 Microscope at 200X
magnification, and Osteomeasure software
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41
37
44
67
63
67

Figure 7: Number of 5-LO protein expression differences among 4 treatment groups:
Rx1_only Media, Rx3_1 µM of ABT, Rx9_1% INS, Rx10_1µM ABT + 1%INS. At both
time points at 24 and 48 hours post-treatment, 5-LO protein expression decreases in both
treatment groups Rx3 (10 µM ABT) and Rx10 (1% INS+10 µM ABT) compared to the
Rx1 (media only) and Rx9 (1.0% INS) (p<0.05), which are denoted by pink and blue
starts. At timepoint of 24 hours post-treatment, 5-LO protein expression increases in Rx9
(1.0% INS) versus Rx1 (only Media), which is denoted by light blue stars. At time point
of 48 hours, 5-LO protein expression increases in Rx10 (1% INS+10 µM ABT) versus
Rx3 (10 µM ABT), which is denoted by red star. When compared to 48 hours posttreatment, 5-LO protein expression in Rx 1 (only media) and Rx 10 (1% INS+10 µM
ABT) increase in 24 hours post treatment. In contrast, there are no differences in 5-LO
protein expression in Rx3 (10 µM ABT) and Rx9 (1.0% INS) in both time points.
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Comparison

Diff of Means
P<0.050
24 hours post treatment
(Rx9 vs Rx10) 1.0% INS vs 1 µM ABT + 1.0% INS
57.000
Yes
(Rx9 vs Rx3) 1.0% INS vs 1 µM ABT
53.000
Yes
(Rx1 vs Rx10) Media only vs 1 µM ABT + 1.0% INS
42.000
Yes
(Rx1 vs Rx3) Media only vs 1 µM ABT
38.000
Yes
(Rx9 vs Rx1) 1.0% INS vs Media only
15.000
Yes
(Rx3 vs Rx10) 1 µM ABT vs 1 µM ABT + 1.0% INS
4.000
No
48 hours post treatment
(Rx9 vs Rx3) 1.0% INS vs 1 µM ABT
57.000
Yes
(Rx1 vs Rx3) Media only vs 1 µM ABT
51.667
Yes
(Rx9 vs Rx10) 1.0% INS vs 1 µM ABT + 1.0% INS
35.667
Yes
(Rx1 vs Rx10) Media only vs 1 µM ABT + 1.0% INS
30.333
Yes
(Rx10 vs Rx 3) 1 µM ABT + 1.0% INS vs 1 µM ABT
21.333
Yes
(Rx9 vs Rx1) 1.0% INS vs Media only
5.333
No
24 hours vs 48 hours post treatment

t

P

10.992

<0.001

10.221

<0.001

8.100

<0.001

7.328

<0.001

2.893

0.040

0.771

0.463

15.513

<0.001

14.062

<0.001

9.707

<0.001

8.256

<0.001

5.806

<0.001

1.452

0.185

Rx1 Media only

13.333

3.502

0.008

25.000

6.565

<0.001

0.333

0.0655

0.949

3.667

0.721

0.742

Yes
Rx 10 1 µM ABT + 1.0% INS
Yes
Rx3 1 µM ABT
No
Rx9 1.0% INS
No

Table 4: statistical analysis for 5-LO protein expression in 4 treatment groups in Figure 8
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The Alcian Blue stain showed that treatment with ABT-761 has negative effect on
matrix proteoglycan deposition (Figure 8) At week 1, the proteoglycan deposition of at
treatment groups (Rx3’_1µM ABT, Rx3_10µM ABT, Rx5_100µM ABT,
Rx10_1%INS+10µM ABT, Rx11_1%INS+100µM ABT) is lower compared to the
positive control (Rx9_1%INS) (p<0.05), except treatment group Rx10’_1%INS+1µM
ABT. Once again, at week 2, the proteoglycan production at all treatment groups
including Rx10’ is lower than positive control Rx9 (p<0.05)(Figure 9). However, Rx3
(10µM ABT) and Rx11 (1%INS+100µM ABT) is lower than negative control Rx1 (only
Media) (p<0.05)(Figure 9, E, F, C, D). Especially, Rx 3’(only 1µM ABT) and
Rx10’(1%INS+1µM ABT) are higher than Rx3, Rx5, Rx11 at which there are a higher
concentration of ABT (p<0.05). Thus, from week 2, there is a possibility of higher
concentrations of ABT which might decrease proteoglycan production has emerged. At
week 3, as there is no statistically significant difference between proteoglycan production
in all treatment groups compared to positive control Rx9 (1%INS) (p>0.05), in other
words, proteoglycan production in all treatment groups starts increasing compared to
decreasing in week 1, and week 2. Also, Rx3’ (1µM ABT) shows higher proteoglycan
deposition versus Rx3 (10µM ABT), Rx5 (100µM ABT), Rx10 (1%INS+10µM ABT),
Rx11 (1%INS+100µM ABT). This further strengthens the possibility that higher
concentrations of ABT can inhibit proteoglycan production. Finally, at week 4, once
again, Rx3’(1µM ABT) and Rx10’(1%INS+1µM ABT) strongly show higher
proteoglycan deposition versus Rx3 (10µM ABT), Rx5 (100µM ABT), Rx10
(1%INS+10µM ABT), Rx11 (1%INS+100µM ABT) (p<0.01). Thus, the Alcian blue
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staining assay result showed that at a concentration of 1µM, ABT-761 has no effect on
proteoglycan deposition of ATDC5 chondrogenic cell line, however, at higher
concentrations, including 10µM and 100µM, ABT-761 has negative effects on
proteoglycan deposition. Alizarin Red Stain also shows that treatment with ABT-761
also has negative effects on calcium deposition of ATDC5 chondrogenic cell line.
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Figure 8: Matrix proteoglycan production in ABT-treated ATDC5 cells overtime. (A)
Quantification of 1uM ABT Treatment groups (B) Images of 1uM ABT Treatment
Groups (C) Quantification of 10uM ABT Treatment groups (D) Images of 10uM ABT
Treatment Groups (E) Quantification of 100uM ABT Treatment groups (F) Images of
10uM ABT Treatment Group. Photographed by the author, Tien My Tran, at Seton Hall
University, South Orange, New Jersey, USA, in May 2019.
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Figure 9: Matrix Calcium Deposition in ABT-treated ATDC5 cells overtime. (A)
Quantification of 1uM ABT Treatment groups (B) Images of 1uM ABT Treatment
Groups (C) Quantification of 10uM ABT Treatment groups (D) Images of 10uM ABT
Treatment Groups (E) Quantification of 100uM ABT Treatment groups (F) Images of
10uM ABT Treatment Groups. Photographed by the author, Tien My Tran, at Seton
Hall University, South Orange, New Jersey, USA, in May 2019 .
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Discussion
ABT-761, a new potent 5-Lipoxygenase inhibitor which effectively inhibits
leukotriene formation has been evaluated both in vitro and in vivo for the treatment of
leukotriene-dependent human diseases. In animal studies, the compound has shown it
potentials in different disease models, including potently attenuates bronchoconstriction
and pulmonary inflammation in rodent (Bell, Harris et al. 1997), or inhibit eosinophil
influx into lungs of Brown Norway rats (Namovic, Walsh et al. 1996), or attenuates
cerebral vasospasm in rabbit model of subarachnoid hemorrhage (Barbosa, Arthur et al.
2001). In fact, ABT-761 is under development for the treatment of asthma in both adults
and children (Reid 2001),(Wong, Kearns et al. 1998). Although, there are studies
demonstrated that pharmacological inhibition of 5-Lipoxygenase can accelerate and
enhances fracture healing or bone formation (Cottrell and O'Connor 2009), (Cottrell,
Keshav et al. 2013), (Saul, Weber et al. 2019). there are no direct studies focusing on the
effects of ABT-761 on chondrogenesis. In this study, through the MTT assay, we found
that ABT-761 at a concentration of 10 µM has no effect on cellular proliferation
compared to the controls (p>0.05) (Figure 5). However, at higher concentrations,
including 100 µM and 1000µM, ABT-761 significantly inhibits cellular proliferation,
which decreases to 63% and 52% respectively, (p<0.05) (Figure 5, Table 2). In addition,
we found that insulin concentration does not make any difference in cellular proliferation
in the presence of ABT (p>0.05), (Figure 5, Table 2). Our data is similar to Steinhibler et
al, who demonstrated that many 5-LO inhibitors have anti-proliferative effects.
Therefore, moving forward from the MTT assay, we omitted the concentration of 1000
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µM, and only used the two concentration of ABT-761 at 10 µM,100 µM, and added one
new concentration of 1 µM to elucidate the effects of ABT-761.
In this study, using immunocytochemistry and immunoblotting, we showed that
ATDC5 cells, which derived from mouse teratocarcinoma chondrogenic cell-like, do
express 5 Lipoxygenase protein, in both proliferation and differentiation phases. 5Lipoxygenase is a key enzyme in the metabolism of arachidonic acid to leukotriene. 5lipoxygenase expression has been shown in various tissue, such as human brain with
traumatic injury and astrocytoma, which is a form of brain tumor, has increased
expression of 5-LO that was demonstrated by immunohistochemistry (Zhang, Zhang et
al. 2006). In addition, using immunofluorescence and immunohistochemistry, 5Lipoxygenase (5-LO) and 15-Lipoxygenase-1 (15-LO-1) have been demonstrated to be
present in rheumatoid arthritis and osteoarthritis synovium, with 5-LO being mostly
expressed in-lining and sub-lining macrophages, neutrophils and mast cells, and 15-LO-1
mainly in lining macrophages, fibroblasts, and sub-lining endothelial cells (Gheorghe,
Korotkova et al. 2009). Leukotriene B4 (LTB4) is a potent chemoattractant associated
with the development of osteoarthritis (OA), its receptors BLT1 and BLT2 have found in
human synovium, subchondral bone as well as in cartilage cells or chondrocytes (Hansen,
Indrevik et al. 2015). In this study, using immunocytochemistry and immunoblotting, we
show that ATDC5 cells, which derived from mouse teratocarcinoma chondrogenic celllike, do express 5 Lipoxygenase protein, in both proliferation and differentiation phases,
in treatments with media only (Rx1) and 1%INS (Rx9) (p<0.01). Nevertheless, the 5-LO
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protein expression is decreased in the presence of the inhibitor, ABT-761 (Rx3_10 µM
ABT and Rx10_ 1%INS+10 µM ABT)(p<0.001) (Figures 6,7,8).
In vertebrates, longitudinal bone growth occurs by a process called endochondral
ossification, which takes place in the growth plates of long bones. Chondrocytes secrete
cartilage matrix, proliferate and differentiate into hypertrophic cells during this process,
resulting in progressive widening of the growth plate ((De Luca, Uyeda et al. 2000). There
are many factors that can influence the longitudinal growth of bone. Nutrition, hormonal,
and mechanical factors can all have effects on cell proliferation, hypertrophy, death and
bone formation. In this study, we demonstrated that at a concentration of 1 µM ABT-761
(Rx3’), there is no increase nor decrease on proteoglycan deposition as well as calcium
deposition compared to controls (Rx1_Media only and Rx9_1%INS) (p<0.05). Moreover,
we strongly found that at higher concentrations of 10 µM (Rx3) and 100 µM of ABT-761
(Rx5), ABT-761 adversely inhibits proteoglycan production or calcium deposition
(p<0.001) (Figures 9.10). In other words, these high concentrations of ABT-761 have
negative effects on chondrogenesis as chondrogenesis is characterized by calcium
deposition

and

proteoglycan

matrix

synthesis.

Furthermore,

as

shown

in

immunocytochemistry assay (Figures 6,7) and immunoblotting assay (Figure 8), in the
presence INS with ABT-761, 5-LO protein decreases as in the presence of inhibitor ABT761 only (Figure 9,10). The markedly negative effects on chondrogenesis of ABT-761 can
contribute to the bone formation by accelerating apoptosis of cartilage, which is
explained by the fact that during chondrogenesis, to promote endochondral ossification,
the mature chondrocytes or cartilage cells must undergo hypertrophy, then apoptosis to
allow cartilage
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become vascularized and osteoblasts invade the cartilage tissue (Quintana, zur Nieden et
al. 2009). From other research that shows that 5-LO causes acceleration in the process of
endochondral ossification and results in the earlier detection of late chondrocyte genes
(Cottrell and O'Connor 2009).
Overall, our experiment results show that treatment with 1µM ABT-761 has no
effect on chondrogenesis, neither increase nor decrease, in ATDC5 cells, a mouse
chondrogenic cell line. In contrast, concentrations of 10 µM and 100µM ABT-761 has
negative effects on chondrogenesis through which ABT-761 promotes chondrocyte
apoptosis that may potentially lead to accelerating endochondral ossification or long bone
formation in patients with a long bone fracture. However, ABT-761 may not be a clinical
value to regenerate or promote chondrogenesis in patients suffering from osteoarthritis.
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